Discontinued — last reported Q4 '19
Merck & Co. Other Intangible Assets, Net increased by 74.2% to $26.68B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 63.0%, from $16.37B to $26.68B. Over 5 years (FY 2020 to FY 2025), Other Intangible Assets, Net shows an upward trend with a 12.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A high value indicates a strong portfolio of intellectual property, while a declining value may signal the approaching expiration of key patents.
This includes identifiable non-physical assets such as patents, trademarks, licenses, and acquired drug rights, net of a...
Crucial for comparing the strength of drug pipelines and competitive advantages among pharmaceutical peers.
other_intangibles_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $519.00M | $13.38B | $22.93B | $23.02B | $22.50B | $21.37B | $20.27B | $19.86B | $19.67B | $19.20B | $18.01B | $17.57B | $16.98B | $17.01B | $16.37B | $15.76B | $15.19B | $15.31B | $26.68B |
| QoQ Change | — | >999% | +71.3% | +0.4% | -2.3% | -5.0% | -5.1% | -2.0% | -1.0% | -2.4% | -6.2% | -2.4% | -3.3% | +0.2% | -3.8% | -3.7% | -3.6% | +0.8% | +74.2% |
| YoY Change | — | — | — | — | >999% | +59.7% | -11.6% | -13.7% | -12.6% | -10.2% | -11.1% | -11.5% | -13.6% | -11.4% | -9.1% | -10.3% | -10.5% | -10.0% | +63.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.